LFB SA, Through rEVO Biologics Subsidiary, Receives Go Ahead from Data Monitoring Committee to Expand Global PERSEPT Phase 3 Program of LR769 in Hemophilia A or B Patients with Inhibitors
March 24, 2015 at 05:24 AM EDT
LFB SA announced today, through its rEVO Biologics subsidiary, that after the planned interim analysis of the PERSEPT 1 safety and ...
